Fig. 2: Tocilizumab impact on progression-free survival.

Kaplan-Meier plot comparing progression-free survival between patients exposed (blue curve) and unexposed (red curve) to tocilizumab (Toci) within 30 days post-administration of CAR T-cell therapy for relapsed/refractory multiple myeloma.